Mittal Life Style Limited (MITTAL.NS)
| Previous Close | 1.8500 |
| Open | 1.9000 |
| Bid | 1.9000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 1.8500 - 1.9000 |
| 52 Week Range | 1.2550 - 3.2500 |
| Volume | |
| Avg. Volume | 761,248 |
| Market Cap | 562.275M |
| Beta (5Y Monthly) | 0.03 |
| PE Ratio (TTM) | 38.00 |
| EPS (TTM) | 0.0500 |
| Earnings Date | May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 03, 2018 |
| 1y Target Est | N/A |
Barrons.com4 Stocks to Play India’s Election
Indian Prime Minister Narendra Modi is likely to win reelection but a pullback in stocks now is an opportunity for investors.
Associated Press FinanceFacing pressure from rights groups, World Bank suspends funding for Tanzania tourism project
The World Bank has suspended funding for a tourism project in Tanzania that caused the suffering of tens of thousands of villagers, according to a U.S.-based rights group that has long urged the global lender to take such action. The World Bank's decision to suspend the $150 million project, which aims to improve the management of natural resources and tourism assets in a remote part of southern Tanzanian, was “long overdue,” the Oakland Institute said in a statement Tuesday, charging that the bank's "failure to take immediate action resulted in serious harms for the local communities.” The suspension of World Bank financing took effect April 18.
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
